NasdaqGS:XERSPharmaceuticals
Assessing Xeris Biopharma Holdings (XERS) Valuation After Profitability Milestone And 2026 Revenue Guidance
What triggered fresh interest in Xeris Biopharma Holdings (XERS)?
Xeris Biopharma Holdings (XERS) has drawn fresh attention after reporting fourth quarter and full year 2025 results that moved from loss to profit, paired with new 2026 revenue guidance and a US$40.7 million shelf registration filing.
See our latest analysis for Xeris Biopharma Holdings.
Despite Xeris Biopharma Holdings posting improved earnings and setting 2026 revenue guidance, recent share price returns have been weak, with...